Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the Q1 FY'25 earnings call transcript of Concord Biotech Limited. The company focuses on organic growth via capacity expansion, new product commercialization, and market expansion. They emphasize operational improvements, regulatory approvals, and scaling up facilities like the Limbasi and upcoming injectable plant. The call highlights growth levers such as increased exports, domestic formulation growth, and CDMO business opportunities without reference to external fundraising. Management continues to stress me

Any current/future capex/capital investment/strategic investment?

Commercial production at the new injectable facility is expected to commence in the current fiscal year, with qualification activities ongoing and expected to complete by Q4 FY '25. The new injectable plant will provide forward integration into finished formulations, offering a competitive edge and significant market opportunity domestically and globally. The company continues to focus on scale-up of the Limbasi API facility, which is progressing well with increasing customer approvals and commercial quantities being purchased. Ongoing investments in expanding product portfolio with 8 to

Future growth expectations in sales/revenue/volumes?

Management expects a CAGR revenue growth of 25% over the next 5 years driven by a strong product pipeline of 8 to 10 new products planned for commercialization in the next 3 to 4 years. Growth levers include scaling up of the Limbasi API facility with increasing customer approvals and volumes. The new injectable formulation facility, expected to commercialize by Q4 FY'25, will contribute to significant growth in the formulation segment from next year onwards. Both API and formulation businesses are anticipated to grow well, maintaining an approximate 80:20 revenue split. Expansion into emergin

Future growth expectations in earnings/operating earnings/profits/EPS?

Concord Biotech aims for a long-term revenue CAGR of 25% over the next 5 years, driven by a robust pipeline of 8-10 new products to be commercialized in the next 3-4 years. Growth levers include scaling up of the Limbasi API facility, commercialization of the injectable plant expected to contribute significantly over the next 18-24 months, and expansion in both API (80%) and Formulation (20%) segments. The company expects stable pricing and market share gains due to less competition globally, especially in complex niche fermentation-based products. EBITDA margins are expected to remain stable

Concord BiotechQ1 FY25Pharmaceuticals & Biotechnology

Concord Biotech Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,374P/E: 53.5Market Cap: ₹15.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Management expects a CAGR revenue growth of 25% over the next 5 years driven by a strong product pipeline of 8 to 10 new products planned for commercialization in the next 3 to 4 years.
Growth levers include scaling up of the Limbasi API facility with increasing customer approvals and volumes.
The new injectable formulation facility, expected to commercialize by Q4 FY'25, will contribute to significant growth in the formulation segment from next year onwards.
Both API and formulation businesses are anticipated to grow well, maintaining an approximate 80:20 revenue split.
Expansion into emerging markets and deeper penetration into developed markets are key strategies for sales growth.
CDMO business development efforts continue, with hopes of generating commercial revenue in the medium term.
The shrinking global competition creates opportunities to gain market shares and add complex niche products with limited competition to the portfolio.

Margin guidance

Category 3

Concord Biotech aims for a long-term revenue CAGR of 25% over the next 5 years, driven by a robust pipeline of 8-10 new products to be commercialized in the next 3-4 years.
Growth levers include scaling up of the Limbasi API facility, commercialization of the injectable plant expected to contribute significantly over the next 18-24 months, and expansion in both API (80%) and Formulation (20%) segments.
The company expects stable pricing and market share gains due to less competition globally, especially in complex niche fermentation-based products.
EBITDA margins are expected to remain stable or improve slightly as injectable formulations with better margins start contributing.
CDMO business offers long-term revenue and profitability upside, though commercial revenues are anticipated in the medium term.
Overall, the management is confident of continued strong earnings and profit growth aligned with the 25% revenue growth guidance.

See what Concord Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the Q1 FY'25 earnings call transcript of Concord Biotech Limited.
The company focuses on organic growth via capacity expansion, new product commercialization, and market expansion.
They emphasize operational improvements, regulatory approvals, and scaling up facilities like the Limbasi and upcoming injectable plant.
The call highlights growth levers such as increased exports, domestic formulation growth, and CDMO business opportunities without reference to external fundraising.
Management continues to stress meeting long-term revenue and EBITDA guidance fueled by internal cash flows and strategic initiatives rather than new external capital raising.

Order book

The transcript provided from Concord Biotech Limited's Q1 FY25 earnings call does not explicitly mention details regarding the current or expected order book or pending orders. However, some relevant points that might indirectly relate to future opportunities and order intake include: - The company has a robust pipeline of 8 to 10 new products planned for commercialization over the next 3 to 4 years. - There is active work on contract development and manufacturing organization (CDMO) opportunities, with several RFQs being filled and ongoing engagements with potential customers. - Growth opportunities exist from new products, new customers, and expanded geographic presence. - The injectable facility is expected to commence commercial production during the fiscal year, which will contribute to growth. - The company sees opportunities from companies shutting down globally, allowing Concord to gain more market share and add complex niche products. No specific figures or quantitative data on order book or pending orders were disclosed in the call.

See what Concord Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes

Commercial production at the new injectable facility is expected to commence in the current fiscal year, with qualification activities ongoing and expected to complete by Q4 FY '25.
The new injectable plant will provide forward integration into finished formulations, offering a competitive edge and significant market opportunity domestically and globally.
The company continues to focus on scale-up of the Limbasi API facility, which is progressing well with increasing customer approvals and commercial quantities being purchased.
Ongoing investments in expanding product portfolio with 8 to 10 new products targeted for commercialization over the next 3 to 4 years, primarily in oncology, anti-infectives, and antifungal segments.
Actively exploring CDMO business opportunities to generate large volumes that will accelerate revenue and margin profile through operating leverage.
These strategic capital investments aim to support long-term revenue CAGR guidance of 25% over five years.

Track Concord Biotech — get its next earnings analysis in your feed

How does Concord Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisConcord Biotech

Rev 2Mar 3

See where Concord Biotech sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Concord Biotech rank in Pharmaceuticals & Biotechnology?

Compare Concord Biotech against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Concord Biotech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →